Dare Bioscience, Inc. current report, 10 January 2020

Dare Bioscience, Inc. (DARE) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on January 10, 2020, by Dare Bioscience, Inc., a Delaware corporation. The filing discloses the entry into a material definitive agreement with Bayer HealthCare LLC regarding the investigational contraceptive product, Ovaprene, for the U.S. market.

Key Financial Metrics and Agreement Terms

The filing details a license agreement with the following financial components:

  • Upfront Payment: $1.0 million received from Bayer.
  • Discretionary Fee: A potential $20.0 million "Clinical Trial and Manufacturing Activities Fee" payable by Bayer after reviewing pivotal clinical trial results. Payment is at Bayer's sole discretion.
  • Milestone Payments: Up to $310.0 million in total potential milestones, including a low double-digit million payment upon the first commercial sale and escalating payments based on annual net sales.
  • Royalties: Tiered royalties starting in the low double digits based on annual net sales, subject to customary reductions.
  • Sublicense Revenue: Dare is entitled to a percentage of sublicense revenue.

The filing does not provide Dare's current revenue, profit, cash flow, margins, debt, or liquidity figures, as this is a current report focused on a specific event rather than a periodic financial statement.

Material Changes and Operational Impact

Under the agreement, Dare retains responsibility for the pivotal trial, development, regulatory activities, and product supply. Bayer will provide advisory support via up to two full-time equivalents. Upon payment of the $20.0 million fee, the license becomes effective, granting Bayer exclusive commercialization rights and co-exclusive development rights in the U.S. The agreement term lasts until the later of patent expiration or 15 years from the first commercial sale.

Outlook, Risks, and Contingencies

Management highlights several material risks and contingencies:

  • Discretionary Payment Risk: Bayer may elect not to pay the $20.0 million fee regardless of clinical trial outcomes, which would prevent the license from becoming effective.
  • Termination Risk: Bayer may terminate the agreement at any time with 90 days' notice. The agreement also automatically terminates if the $20.0 million fee is not paid when due.
  • Commercialization Risk: Future milestone and royalty payments depend on successful regulatory approval and commercialization, which faces competition from existing and developing alternative products.
  • Forward-Looking Statements: The report contains forward-looking statements regarding potential payments and development timelines, which are subject to significant uncertainties.

Investor Verification Checklist

  • Verify the receipt of the $1.0 million upfront payment in Dare's cash position.
  • Monitor the status of the pivotal clinical trial for Ovaprene to assess the likelihood of the $20.0 million discretionary fee.
  • Review the full license agreement (to be filed in the 2019 Form 10-K) for specific termination clauses and royalty calculation details.
  • Assess the competitive landscape for contraceptive products in the U.S. to evaluate the commercial viability of Ovaprene.
  • Confirm whether Dare has elected to use the extended transition period for new accounting standards as an emerging growth company.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.